DOCSLIB.ORG

Modulation of STAT Signaling by STAT-Interacting Proteins

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Modulation of STAT Signaling by STAT-Interacting Proteins Oncogene (2000) 19, 2638 ± 2644 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Modulation of STAT signaling by STAT-interacting proteins K Shuai*,1 1Departments of Medicine and Biological Chemistry, University of California, Los Angeles, California, CA 90095, USA STATs (signal transducer and activator of transcription) play important roles in numerous cellular processes Interaction with non-STAT transcription factors including immune responses, cell growth and dierentia- tion, cell survival and apoptosis, and oncogenesis. In Studies on the promoters of a number of IFN-a- contrast to many other cellular signaling cascades, the induced genes identi®ed a conserved DNA sequence STAT pathway is direct: STATs bind to receptors at the named ISRE (interferon-a stimulated response element) cell surface and translocate into the nucleus where they that mediates IFN-a response (Darnell, 1997; Darnell function as transcription factors to trigger gene activa- et al., 1994). Stat1 and Stat2, the ®rst known members tion. However, STATs do not act alone. A number of of the STAT family, were identi®ed in the transcription proteins are found to be associated with STATs. These complex ISGF-3 (interferon-stimulated gene factor 3) STAT-interacting proteins function to modulate STAT that binds to ISRE (Fu et al., 1990, 1992; Schindler et signaling at various steps and mediate the crosstalk of al., 1992). ISGF-3 consists of a Stat1:Stat2 heterodimer STATs with other cellular signaling pathways. This and a non-STAT protein named p48, a member of the article reviews the roles of STAT-interacting proteins in IRF (interferon regulated factor) family (Levy, 1997). the regulation of STAT signaling. Oncogene (2000) 19, p48 alone can bind to ISRE weakly. Although Stat1 2638 ± 2644. and Stat2 can not bind to ISRE without p48, the ISGF3 complex has a high binding anity toward Keywords: STAT-interacting proteins; signal transduc- ISRE. The ISGF3 complex established a paradigm in tion; transcription which STAT proteins may aect transcription by modulating other non-STAT transcription factors. In fact, since STAT proteins were ®rst identi®ed through Introduction the characterization of ISGF3, it had been questioned whether STATs alone can bind to DNA. Characteriza- In unstimulated cells, a STAT protein exists in the tion of IFN-g-induced gene activation demonstrated cytoplasm as a monomer. Upon activation by that Stat1 is a sequence speci®c DNA binding protein tyrosine phosphorylation in response to ligand that drives transcription through GAS (g-activation stimulation, STAT forms a dimer through SH2- site) (Decker et al., 1991; Shuai et al., 1992). It now phosphotyrosyl interactions (Becker et al., 1998; Chen appears that a STAT protein may participate in et al., 1998; Shuai et al., 1994). The STAT dimer transcriptional activation through four distinct me- then translocates into the nucleus to activate chanisms: (1) A STAT protein may bind to its own transcription. It is believed that the STAT dimer is DNA target site to directly drive transcription; (2) A dephosphorylated by an unidenti®ed protein tyrosine STAT protein may form a transcriptional complex phosphatase (PTPase) to form non-phosphorylated with a non-STAT transcription factor to trigger STAT monomers in the nucleus (Darnell, 1997; transcription through a STAT; or (3) a non-STAT Shuai, 1999). The inactivated STAT monomer is DNA binding element; (4) A STAT and a non-STAT relocated back to the cytoplasm where it can be transcription factor may cooperate to activate tran- reactivated, completing an activation-inactivation scription through binding to clustered independent cycle (Figure 1). The hypothesis that a STAT can DNA binding sites (Figure 2). shuttle between cytoplasm and nucleus was initially derived from results of biochemical fractionation and p48 pulse-chase experiments (Haspel and Darnell, 1999; Haspel et al., 1996), and is clearly supported by The molecular basis of ISGF3 complex formation has recent studies using GFP (green ¯uorescence protein) been extensively studied. Although Stat1, Stat2 and p48 fusion proteins to visualize the tracking of Stat1 in can form a stable complex in the presence of DNA, initial living cells (Keoster and Hauser, 1999). A number of attempts to detect association of Stat1 or Stat2 with p48 proteins have been identi®ed that interact with in solution had failed. Subsequently, in vivo coimmuno- STATs and modulate the activity of STATs at precipitation studies using speci®c antibodies against p48 various steps of the activation-inactivation cycle or Stat2 demonstrated that Stat2 can interact with p48 in (Figure 1). The focus of this article is to review the the absence of DNA (Martinez-Moczygemba et al., roles of these STAT-interacting proteins in STAT 1997). The Stat2-p48 interaction was detectable in cells signaling. with or without IFN-a treatment. But similar coimmu- noprecipitation analysis failed to detect an interaction between Stat1 and p48. These results suggest that either Stat1 does not interact with p48 in solution in vivo,or *Correspondence: K Shuai, Division of Hematology-Oncology, 11- alternatively, the interaction of p48 and Stat1 is weak 934 Factor Bldg, 10833 LeConte Avenue, Los Angeles, California and transient in the absence of the DNA target. 90095-1678. Consistent with the latter hypothesis, the Stat1-p48 STAT-interacting proteins K Shuai 2639 Figure 1 The activation and inactivation cycle of STAT. STAT shuttles between cytoplasm and nucleus. STAT-interacting proteins aect various steps of STAT signaling. See text for detailed description Figure 2 Mechanisms of transcriptional activation by STATs. STATs alone or in cooperation with non-STAT transcription factors activate transcription through a STAT site or a non-STAT site in gene promoters. See text for details interaction was observed when analysed by the yeast al., 1997) (Figure 3). The coiled-coil domain of Stat2 is two-hybrid assay, a highly sensitive method to detect essential for Stat2-p48 interaction. A single mutation protein-protein interactions. In addition, in vitro GST (K161A) in the p48 contact region of Stat1 inhibited pull-down experiments suggested that both Stat1 and the Stat1-p48 interaction as well as the IFN-a-triggered Stat2 can interact with p48, although the Stat2-p48 ISG15 gene induction, whereas this mutation had no interaction is several fold stronger than the Stat1-p48 eect on either the Stat1-Stat2 interaction or the IFN-g association (Horvath et al., 1996). response which is independent of p48 (Horvath et al., In vitro reconstitution experiments identi®ed the 1996). These results strongly support the importance of COOH-terminal region of p48 (aa 217 ± 377) is required the Stat1-p48 interaction in IFN-a signaling. for ISGF3 formation (Veals et al., 1992). Detailed domain mapping studies suggest that the NH2-terminal c-Jun and Sp1 region of Stat1 (aa 152 ± 239) or Stat2 (aa 1 ± 324 in Stat2) contacts with the COOH-terminal portion of It has been well established that the transcriptional p48 (Horvath et al., 1996; Martinez-Moczygemba et activation of mammalian genes usually requires the Oncogene STAT-interacting proteins K Shuai 2640 Figure 3 Regions of STATs involved in binding to non-STAT proteins. The domain structure of STAT is shown. The contact regions of STAT-interacting proteins are underlined. ND: the N domain; CCD: Coiled coil domain; DBD: DNA binding domain; LD: Linker domain; SH2: Src homology 2 domain; TAD: Transcription activation domain cooperative eect of many transcription factors. (Figure 3). Point mutations in the interaction regions Studies on a number of genes have shown that of Stat3 abolished Stat3-c-Jun interaction as well as independent but closely spaced DNA binding sites for their cooperation in IL-6-induced transcriptional STAT and other transcription factors are required for activation of the a2-macroglobulin gene. Further- maximal transcriptional activation. Two well studied more, these mutations did not aect the ability of examples involving cooperative interactions between Stat3 to drive noncooperative IL-6-induced transcrip- STAT and Sp1 or STAT and c-Jun are discussed in tion. It is unclear why dierent regions of c-Jun detail here. were observed to interact with Stat3 by dierent The intercellular adhesion molecule-1 (ICAM-1) investigators. Nevertheless, these results demonstrate gene is induced by IFN-g. In the promoter of ICAM- the importance of the Stat3-c-Jun interaction in gene 1 gene, contiguous but independent DNA binding sites activation. for Stat1 and Sp1 are present and are shown to be required for the full transcriptional activation of Glucocortical receptor ICAM-1 gene in response to IFN-g. (Look et al., 1995). Similarly, both a Stat3 binding sequence and an The ®nding that glucocorticoid receptor (GR) is adjacent Sp1 binding site present in the promoter of associated with Stat5 came from studies on the b- the C/EBPd (CCAAT/enhancer binding protein d) gene casein gene. Upon interaction with its steroid ligand, are shown to be required for the induction of C/EBPd GR binds to speci®c DNA sequence, the glucocorti- by IL-6 (Cantwell et al., 1998). In addition, Stat1 and coid response element (GRE) to activate transcrip- Sp1 association in solution has been observed. These tion (Beato et al., 1995). The optimal expression of studies demonstrate that Stat1 or Stat3 can cooperate b-casein gene is achieved when costimulated with with Sp1 to activate genes. glucocorticoids and prolactin (PRL), a growth The involvement of Stat3 and c-Jun cooperation hormone that activates Stat5 (Schmitt-Ney et al., in transcriptional activation has been well documen- 1991). A functional Stat5 binding site and half- ted for a number of genes, including the induction palindromic GREs are present in the promoter of b- of a2-macroglobulin gene by IL-6 (Ito et al., 1989), casein gene. Mutation of the Stat5 binding site in the induction of c-fos by multiple ligands (Robertson the b-casein gene promoter abolishes both glucocor- et al., 1995), the induction of matrix metalloprotei- ticoid- and PRL-induced transcription.
Load more

Recommended publications
  • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
    Published OnlineFirst October 26, 2016; DOI: 10.1158/2159-8290.CD-15-1263 RESEARCH ARTICLE The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer Jennifer L. Bishop1, Daksh Thaper1,2, Sepideh Vahid1,2, Alastair Davies1, Kirsi Ketola1, Hidetoshi Kuruma1, Randy Jama1, Ka Mun Nip1,2, Arkhjamil Angeles1, Fraser Johnson1, Alexander W. Wyatt1,2, Ladan Fazli1,2, Martin E. Gleave1,2, Dong Lin1, Mark A. Rubin3, Colin C. Collins1,2, Yuzhuo Wang1,2, Himisha Beltran3, and Amina Zoubeidi1,2 ABSTRACT Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mecha- nistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with clas- sic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. SIGNIFICANCE: Understanding the contribution of the AR to the emergence of highly lethal, drug- resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design.
    [Show full text]
  • The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
    Author Manuscript Published OnlineFirst on September 25, 2018; DOI: 10.1158/1535-7163.MCT-18-0508 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The STAT3 inhibitor galiellalactone reduces IL6-mediated AR activity in benign and malignant prostate models Florian Handle1,2, Martin Puhr1, Georg Schaefer3, Nicla Lorito1, Julia Hoefer1, Martina Gruber1, Fabian Guggenberger1, Frédéric R. Santer1, Rute B. Marques4, Wytske M. van Weerden4, Frank Claessens2, Holger H.H. Erb5*, Zoran Culig1* 1 Division of Experimental Urology, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria 2 Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium 3 Department of Pathology, Medical University of Innsbruck, Innsbruck, Austria 4 Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands 5 Department of Urology and Pediatric Urology, University Medical Center Mainz, Mainz, Germany *Joint senior authors Running title: Galiellalactone reduces IL6-mediated AR activity Conflict of interest statement: Zoran Culig received research funding and honoraria from Astellas. Other authors declare no potential conflict of interest. Keywords (5): Prostate cancer, androgen receptor, Interleukin-6, STAT3, galiellalactone Financial support: This work was supported by grants from the Austrian Cancer Society/Tirol (to F. Handle) and the Austrian Science Fund (FWF): W1101-B12 (to Z. Culig). Corresponding author: Prof. Zoran Culig, Medical University of Innsbruck, Division of Experimental Urology, Anichstr. 35 6020 Innsbruck, Austria, [email protected] Word counts: Abstract: 242 (limit: 250); Text: 4993 (limit: 5000) Handle et al., 2018 1 Downloaded from mct.aacrjournals.org on October 1, 2021.
    [Show full text]
  • Quantitative Modelling Explains Distinct STAT1 and STAT3
    bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title Quantitative modelling explains distinct STAT1 and STAT3 activation dynamics in response to both IFNγ and IL-10 stimuli and predicts emergence of reciprocal signalling at the level of single cells. 1,2, 3 1 1 1 1 1 2 Sarma U , Maitreye M , Bhadange S , Nair A , Srivastava A , Saha B , Mukherjee D . 1: National Centre for Cell Science, NCCS Complex, Ganeshkhind, SP Pune University Campus, Pune 411007, India. 2 : Corresponding author. [email protected] , [email protected] 3: Present address. Labs, Persistent Systems Limited, Pingala – Aryabhata, Erandwane, Pune, 411004 India. bioRxiv preprint doi: https://doi.org/10.1101/425868; this version posted September 24, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Abstract Cells use IFNγ-STAT1 and IL-10-STAT3 pathways primarily to elicit pro and anti-inflammatory responses, respectively. However, activation of STAT1 by IL-10 and STAT3 by IFNγ is also observed. The regulatory mechanisms controlling the amplitude and dynamics of both the STATs in response to these functionally opposing stimuli remains less understood. Here, our experiments at cell population level show distinct early signalling dynamics of both STAT1 and STAT3(S/1/3) in responses to IFNγ and IL-10 stimulation.
    [Show full text]
  • Viral Resistance and IFN Signaling in STAT2 Knockout Fish Cells Carola E
    Viral Resistance and IFN Signaling in STAT2 Knockout Fish Cells Carola E. Dehler, Katherine Lester, Giulia Della Pelle, Luc Jouneau, Armel Houel, Catherine Collins, Tatiana Dovgan, This information is current as Radek Machat, Jun Zou, Pierre Boudinot, Samuel A. M. of September 26, 2021. Martin and Bertrand Collet J Immunol published online 29 May 2019 http://www.jimmunol.org/content/early/2019/05/28/jimmun ol.1801376 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/05/28/jimmunol.180137 Material 6.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published May 29, 2019, doi:10.4049/jimmunol.1801376 The Journal of Immunology Viral Resistance and IFN Signaling in STAT2 Knockout Fish Cells Carola E. Dehler,* Katherine Lester,† Giulia Della Pelle,‡ Luc Jouneau,‡ Armel Houel,‡ Catherine Collins,† Tatiana Dovgan,*,† Radek Machat,‡,1 Jun Zou,*,2 Pierre Boudinot,‡ Samuel A.
    [Show full text]
  • A Molecular Switch from STAT2-IRF9 to ISGF3 Underlies Interferon-Induced Gene Transcription
    ARTICLE https://doi.org/10.1038/s41467-019-10970-y OPEN A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription Ekaterini Platanitis 1, Duygu Demiroz1,5, Anja Schneller1,5, Katrin Fischer1, Christophe Capelle1, Markus Hartl 1, Thomas Gossenreiter 1, Mathias Müller2, Maria Novatchkova3,4 & Thomas Decker 1 Cells maintain the balance between homeostasis and inflammation by adapting and inte- grating the activity of intracellular signaling cascades, including the JAK-STAT pathway. Our 1234567890():,; understanding of how a tailored switch from homeostasis to a strong receptor-dependent response is coordinated remains limited. Here, we use an integrated transcriptomic and proteomic approach to analyze transcription-factor binding, gene expression and in vivo proximity-dependent labelling of proteins in living cells under homeostatic and interferon (IFN)-induced conditions. We show that interferons (IFN) switch murine macrophages from resting-state to induced gene expression by alternating subunits of transcription factor ISGF3. Whereas preformed STAT2-IRF9 complexes control basal expression of IFN-induced genes (ISG), both type I IFN and IFN-γ cause promoter binding of a complete ISGF3 complex containing STAT1, STAT2 and IRF9. In contrast to the dogmatic view of ISGF3 formation in the cytoplasm, our results suggest a model wherein the assembly of the ISGF3 complex occurs on DNA. 1 Max Perutz Labs (MPL), University of Vienna, Vienna 1030, Austria. 2 Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna 1210, Austria. 3 Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria. 4 Research Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna 1030, Austria.
    [Show full text]
  • Activation of Smad Transcriptional Activity by Protein Inhibitor of Activated STAT3 (PIAS3)
    Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3) Jianyin Long*†‡, Guannan Wang*†‡, Isao Matsuura*†‡, Dongming He*†‡, and Fang Liu*†‡§ *Center for Advanced Biotechnology and Medicine, †Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, and ‡Cancer Institute of New Jersey, 679 Hoes Lane, Piscataway, NJ 08854 Communicated by Allan H. Conney, Rutgers, The State University of New Jersey, Piscataway, NJ, November 17, 2003 (received for review August 22, 2003) Smad proteins play pivotal roles in mediating the transforming of many transcription factors through distinct mechanisms. growth factor ␤ (TGF-␤) transcriptional responses. We show in this PIAS1 and PIAS3 bind and inhibit STAT1 and STAT3 DNA- report that PIAS3, a member of the protein inhibitor of activated binding activities, respectively (19, 20). PIASx␣ and PIASx␤ STAT (PIAS) family, activates TGF-␤͞Smad transcriptional re- were identified through interactions with the androgen receptor sponses. PIAS3 interacts with Smad proteins, most strongly with and the homeodomain protein Msx2, respectively (21, 22). Smad3. PIAS3 and Smad3 interact with each other at the endog- PIASx␣ and PIASx␤ inhibit IL12-mediated and STAT4- enous protein level in mammalian cells and also in vitro, and the dependent gene activation (23). PIAS1, PIAS3, PIASx␣, and association occurs through the C-terminal domain of Smad3. We PIASx␤ also regulate transcriptional activation by various ste- further show that PIAS3 can interact with the general coactivators roid receptors (21, 24–26). PIASy has been shown to antagonize p300͞CBP, the first evidence that a PIAS protein can associate with the activities of STAT1 (27), androgen receptor (28), p53 (29), p300͞CBP.
    [Show full text]
  • IRF8 Regulates Gram-Negative Bacteria–Mediated NLRP3 Inflammasome Activation and Cell Death
    IRF8 Regulates Gram-Negative Bacteria− Mediated NLRP3 Inflammasome Activation and Cell Death This information is current as Rajendra Karki, Ein Lee, Bhesh R. Sharma, Balaji Banoth of September 25, 2021. and Thirumala-Devi Kanneganti J Immunol published online 23 March 2020 http://www.jimmunol.org/content/early/2020/03/20/jimmun ol.1901508 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2020/03/20/jimmunol.190150 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 25, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2020 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published March 23, 2020, doi:10.4049/jimmunol.1901508 The Journal of Immunology IRF8 Regulates Gram-Negative Bacteria–Mediated NLRP3 Inflammasome Activation and Cell Death Rajendra Karki,*,1 Ein Lee,*,†,1 Bhesh R. Sharma,*,1 Balaji Banoth,* and Thirumala-Devi Kanneganti* Inflammasomes are intracellular signaling complexes that are assembled in response to a variety of pathogenic or physiologic stimuli to initiate inflammatory responses.
    [Show full text]
  • An Immunoevasive Strategy Through Clinically-Relevant Pan-Cancer Genomic and Transcriptomic Alterations of JAK-STAT Signaling Components
    bioRxiv preprint doi: https://doi.org/10.1101/576645; this version posted March 14, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components Wai Hoong Chang1 and Alvina G. Lai1, 1Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford, OX3 7FZ, United Kingdom Since its discovery almost three decades ago, the Janus ki- Although cytokines are responsible for inflammation in nase (JAK)-signal transducer and activator of transcription cancer, spontaneous eradication of tumors by endoge- (STAT) pathway has paved the road for understanding inflam- nous immune processes rarely occurs. Moreover, the matory and immunity processes related to a wide range of hu- dynamic interaction between tumor cells and host immu- man pathologies including cancer. Several studies have demon- nity shields tumors from immunological ablation, which strated the importance of JAK-STAT pathway components in overall limits the efficacy of immunotherapy in the clinic. regulating tumor initiation and metastatic progression, yet, the extent of how genetic alterations influence patient outcome is far from being understood. Focusing on 133 genes involved in Cytokines can be pro- or anti-inflammatory and are inter- JAK-STAT signaling, we found that copy number alterations dependent on each other’s function to maintain immune underpin transcriptional dysregulation that differs within and homeostasis(3).
    [Show full text]
  • Role of Perforin-2 in Regulating Type I Interferon Signaling
    https://www.scientificarchives.com/journal/journal-of-cellular-immunology Journal of Cellular Immunology Review Article Role of Perforin-2 in Regulating Type I Interferon Signaling Gregory V Plano, Noula Shembade* Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center Miller School of Medicine, University of Miami, Miami, FL 33136, USA *Correspondence should be addressed to Noula Shembade; [email protected] Received date: November 21, 2020, Accepted date: February 02, 2021 Copyright: © 2021 Plano G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Sepsis is a systemic inflammatory response caused by a harmful host immune reaction that is activated in response to microbial infections. Infection-induced type I interferons (IFNs) play critical roles during septic shock. Type I IFNs initiate their biological effects by binding to their transmembrane interferon receptors and initiating the phosphorylation and activation of tyrosine kinases TYK2 and JAK1, which promote phosphorylation and activation of STAT molecules. Type I IFN-induced activation of JAK/STAT pathways is a complex process and not well understood. Improper regulation of type I IFN responses can lead to the development of infectious and inflammation-related diseases, including septic shock, autoimmune diseases, and inflammatory syndromes. This review is mainly focused on the possible mechanistic roles of the transmembrane Perforin-2 molecule in the regulation of type I IFN- induced signaling. Keywords: JAK/STAT, Interferons, TYK2, STATs, Perforin-2, IFNAR1, IFNAR2 and Signaling Introduction and activator of transcription 2), respectively, under normal physiological conditions [4,5].
    [Show full text]
  • 1541-7786.MCR-09-0417.Full.Pdf
    Published Online First on April 6, 2010 Cell Cycle, Cell Death, and Senescence Molecular Cancer Research The Intracellular Delivery of a Recombinant Peptide Derived from the Acidic Domain of PIAS3 Inhibits STAT3 Transactivation and Induces Tumor Cell Death Corina Borghouts, Hanna Tittmann, Natalia Delis, Marisa Kirchenbauer, Boris Brill, and Bernd Groner Abstract Signaling components, which confer an “addiction” phenotype on cancer cells, represent promising drug tar- gets. The transcription factor signal transducers and activators of transcription 3 (STAT3) is constitutively ac- tivated in many different types of tumor cells and its activity is indispensible in a large fraction. We found that the expression of the endogenous inhibitor of STAT3, protein inhibitor of activated STAT3 (PIAS3), positively correlates with STAT3 activation in normal cells. This suggests that PIAS3 controls the extent and the duration of STAT3 activity in normal cells and thus prevents its oncogenic function. In cancer cells, however, the ex- pression of PIAS3 is posttranscriptionally suppressed, possibly enhancing the oncogenic effects of activated STAT3. We delimited the interacting domains of STAT3 and PIAS3 and identified a short fragment of the COOH-terminal acidic region of PIAS3, which binds strongly to the coiled-coil domain of STAT3. This PIAS3 fragment was used to derive the recombinant STAT3-specific inhibitor rPP-C8. The addition of a protein trans- duction domain allowed the efficient internalization of rPP-C8 into cancer cells. This resulted in the suppression of STAT3 target gene expression, in the inhibition of migration and proliferation, and in the induction of μ apoptosis at low concentrations [half maximal effective concentration (EC50), <3 mol/L].
    [Show full text]
  • Signal Transducer and Activator of Transcription 5A/B in Prostate and Breast Cancers
    Endocrine-Related Cancer (2008) 15 367–390 REVIEW Signal transducer and activator of transcription 5A/B in prostate and breast cancers Shyh-Han Tan and Marja T Nevalainen Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, BLSB 309, Philadelphia, Pennsylvania 19107, USA (Correspondence should be addressed to M T Nevalainen; Email: [email protected]) Abstract Protein kinase signaling pathways, such as Janus kinase 2-Signal transducer and activator of transcription 5A/B (JAK2-STAT5A/B), are of significant interest in the search for new therapeutic strategies in both breast and prostate cancers. In prostate cancer, the components of the JAK2- STAT5A/B signaling pathway provide molecular targets for small-molecule inhibition of survival and growth signals of the cells. At the same time, new evidence suggests that the STAT5A/B signaling pathway is involved in the transition of organ-confined prostate cancer to hormone- refractory disease. This implies that the active JAK2-STAT5A/B signaling pathway potentially provides the means for pharmacological intervention of clinical prostate cancer progression. In addition, active STAT5A/B may serve as a prognostic marker for identification of those primary prostate cancers that are likely to progress to aggressive disease. In breast cancer, the role of STAT5A/B is more complex. STAT5A/B may have a dual role in the regulation of malignant mammary epithelium. Data accumulated from mouse models of breast cancer suggest that in early stages of breast cancer STAT5A/B may promote malignant transformation and enhance growth of the tumor. This is in contrast to established breast cancer, where STAT5A/B may mediate the critical cues for maintaining the differentiation of mammary epithelium.
    [Show full text]
  • Identifying the Role of Wilms Tumor 1 Associated Protein in Cancer Prediction Using Integrative Genomic Analyses
    MOLECULAR MEDICINE REPORTS 14: 2823-2831, 2016 Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses LI‑SHENG WU1*, JIA-YI QIAN2*, MINGHAI WANG3* and HAIWEI YANG4 1Department of General Surgery, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001; 2Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 3Department of General Surgery, The First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002; 4Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China Received August 31, 2015; Accepted June 2, 2016 DOI: 10.3892/mmr.2016.5528 Abstract. The Wilms tumor suppressor, WT1 was first iden- regulatory factor 1, glucocorticoid receptor and peroxisome tified due to its essential role in the normal development of proliferator‑activated receptor γ transcription factor binding the human genitourinary system. Wilms tumor 1 associated sites were identified in the upstream (promoter) region of the protein (WTAP) was subsequently revealed to interact with human WTAP gene, suggesting that these transcription factors WT1 using yeast two‑hybrid screening. The present study may be involved in WTAP functions in tumor formation. identified 44 complete WTAP genes in the genomes of verte- brates, including fish, amphibians, birds and mammals. The Introduction vertebrate WTAP proteins clustered into the primate, rodent and teleost lineages using phylogenetic tree analysis. From The Wilms tumor suppressor gene WT1 was first identified 1,347 available SNPs in the human WTAP gene, 19 were due to its essential role in the normal development of the identified to cause missense mutations.
    [Show full text]